title: The newly developed inhaled corticosteroid ciclesonide for the treatment of asthma.
abstract: Ciclesonide is the most recently developed inhaled corticosteroid for the treatment of asthma to enter global markets. It has been formulated as an aerosol solution in a metered dose inhaler with hydrofluoralkane. The mass median aerodynamic diameter of aerosolised ciclesonide is 1 - 2 microm, providing excellent lung deposition characteristics. Ciclesonide can undergo reversible esterification in the lungs, possibly allowing once-daily dosing, and is highly protein bound, possibly leading to reduced systemic side effects. Clinical trials suggest that ciclesonide effectively controls asthma and has a favourable safety profile.
authors.affiliation: Pulmonary, Critical Care and Respiratory Services, Washington Hospital Center, 110 Irving Street, NW, Washington, DC 20010, USA. Gene.Colice@Medstar.net
authors.forename: Gene L
authors.initials: GL
authors.lastname: Colice
mesh_terms: D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001985:Bronchial Provocation Tests; D002648:Child; D006801:Humans; D006854:Hydrocortisone / Q000097:blood / Q000652:urine; D011282:Pregnenediones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000305:Adrenal Cortex Hormones; D011282:Pregnenediones; C120481:ciclesonide; D006854:Hydrocortisone